Qiagen stock trades at EUR 45.05, down 0.49% pre-Xetra
Published on 11/06/2026 at 08:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat matters before the open
- QIAGEN serves more than 500,000 customers working to advance science and improve health.
- The company highlights five growth pillars, a strong balance sheet and a track record of solid operating cash flow.
Qiagen stock traded at EUR 45.05 on Lang & Schwarz at 8:25 CET on Friday, November 6, 2026, 0.49 percent below the Xetra close of Thursday, November 5, 2026, at EUR 45.27.
QIAGEN says it serves more than 500,000 customers seeking to advance science and improve health. Its Investor Relations page highlights leading positions in attractive markets, a strategy built around five growth pillars, a strong balance sheet and healthy operating cash flow.
Business profile remains central
For investors, the company profile keeps the focus on recurring demand from research and healthcare customers, while the balance sheet and cash generation support capital allocation. The premarket indication remains below the latest Xetra close as European trading approaches.
For a real-time quote of Qiagen stock, investors can follow the latest market indication.
The AEX provides the relevant Dutch market backdrop for the session.
More news and analyses on Qiagen stock remain available as the takeover-related investor debate develops.
